Search Results for "Brilinta Sales"

22:58 EST 30th January 2015 | BioPortfolio

Original Source: Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It reduces the clumping of blood particles, called platelets,...

Matching Channels

Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It re...

Sales Jobs

Pfizer

Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have ...

Boehringer Ingelheim

Boehringer Ingelheim is a global pharmaceutical company with annual sales of over $16 billion, making it the 10th largest pharmaceutical company in the world based on sales.  With bases in 47 c...

Plavix

Plavix is a clot-busting drug, produced by Bristol-Myers Squibb Company, and reached annual sales in 2009 of $4.2m, making the third highest drug in the world (based on 2009 annual sales). Prescri...

Matching News

AstraZeneca’s Brilinta Gives Brilliant Sales Performance

AstraZeneca’s cardiovascular drug Brilinta – one of the group’s five key growth platforms - seems to have turned the corner to give a stellar performance in the second quarter – particularly i...

AstraZeneca Releases Phase 4 Brilinta Data

AstraZeneca announced the results of the Phase 4 ATLANTIC study, which indicates that the profile of Brilinta/Brilique (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital ...

Mixed results for AZ’s troubled Brilinta

The latest trial for AstraZeneca’s heart drug Brilinta (ticagrelor) has failed to meet expected results but suggests more flexible applications for the drug are possible. The results of the Phase IV...

AstraZeneca’s troubled Brilinta gets welcome lift

AstraZeneca has reported positive primary endpoint results for its anti-clogging drug Brilinta to treat patients who have had a heart attack or severe chest pains. Clinical trials involving over 21,00...

ESC: No Pre-PCI Boost from Brilinta in Ambulance (CME/CE)

BARCELONA (MedPage Today) -- Giving the antiplatelet drug ticagrelor (Brilinta) in the ambulance to patients with acute ST-segment elevation myocardial infarction didn't improve coronary reperfusion b...

AstraZeneca bolsters defences with strong sales

AstraZeneca (LON:AZN) primed its defences against another assault from US pharma Pfizer by blasting past forecasts helped by a surge in sales of heart drug Brilinta. Sales rose by 4% to US$6.45bn (&po...

U.S. DoJ Clears AstraZeneca Over Brilinta PLATO Trial

AstraZeneca’s “all-clear” from the U.S. Department of Justice over Brilinta’s PLATO trial removes a dark cloud from the heart drug’s prospects and strengthens the pure pharma’s argument t...

AstraZeneca developing reversal agent for blood-thinner Brilinta

LONDON, Nov 13 (Reuters) - AstraZeneca is developing an antibody treatment to rapidly reverse the blood-thinning effects of its heart drug Brilinta in rare emergency situations, such as urgent surgery...

Matching PubMed Articles

Understanding Community Norms Surrounding Tobacco Sales.

In the US, denormalizing tobacco use is key to tobacco control; less attention has been paid to denormalizing tobacco sales. However, some localities have placed limits on the number and type of retai...

Variations in the sales and sales patterns of veterinary antimicrobial agents in 25 European countries.

To describe sales and sales patterns of veterinary antimicrobial agents in 25 European Union (EU)/European Economic Area (EEA) countries for 2011.

Antidepressant sales and the risk for alcohol-related and non-alcohol-related suicide in Finland-an individual-level population study.

A marked decline in suicide rates has co-occurred with increased antidepressant sales in several countries but the causal connection between the trends remains debated. Most previous studies have focu...

Retail Impact of Raising Tobacco Sales Age to 21 Years.

The majority of tobacco use emerges in individuals before they reach 21 years of age, and many adult distributors of tobacco to youths are young adults aged between 18 and 20 years. Raising the tobacc...

Occupational fatalities among driver/sales workers and truck drivers in the United States, 2003-2008.

This study provides a national profile of occupational fatalities among truck drivers and driver-sales workers.

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement